ThromboGenics®
Advancing Science. Enhancing Vision.™

Regulated Information - Transparency Statement

Leuven, Belgium, 8 December 2015 – Pursuant to Belgian transparency legislation (Law of 2 May 2007), ThromboGenics NV (Euronext Brussels: THR) received a transparency notification on 23 November 2015 from **Mr Landon T. Clay** and controlled entities (*East Hill Hedge Fund LLC, Monadnock Charitable Lead Annuity Trust, Clay Fellowships Charitable Trust en The Clay Mathematics Institute, Inc., or the 'East Hill Management Company LLC*), and from **Thomas M Clay** and controlled entities.

Landon T. Clay notified that on 20 November 2015, 3,337,182 shares, representing 9.25 % of the current 36,094,349 outstanding ThromboGenics shares, were held by himself and controlled entities.

Thomas M. Clay notified that on 20 November 2015, the ThromboGenics shares held by himself and controlled entities have fallen below 3%.

On November 23, 2015, based on all received transparency declarations received, ThromboGenics NV is aware of the following participations:

Shareholder	**number of securities**	**% of voting rights**
Mr Landon T. Clay and entities controlled by him	3,337,182	9.25%
Norges Bank	1,065,605	2.95%
Baron Philippe Vlerick and entities controlled by him	2,324,719	6.44%

END

For further information please contact:

ThromboGenics	**Citigate Dewe Rogerson**
Wouter Piepers, Global Head of Corporate Communications & IR +32 16 75 13 10 / +32 478 33 56 32 wouter.piepers@thrombogenics.com	David Dible/Malcolm Robertson Tel: +44 20 7282 2867 Malcolm.robertson@citigatedr.co.uk

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for diabetic eye disease.

The Company's first product, JETREA® (ocriplasmin), has been approved in 53 countries across the globe. In the US, ThromboGenics is commercializing JETREA® via its subsidiary ThromboGenics inc. ThromboGenics signed an agreement with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States.

ThromboGenics is planning a Phase II clinical trial with JETREA® in diabetic retinopathy. Next to JETREA®, the company is in the midst of evaluating a number of potential candidates for next generation treatments in diabetic eye disease.

ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.